🇺🇸 FDA
Patent

US 7345054

Heterocyclic inhibitors of ERK2 and uses thereof

granted A61PA61P35/00

Quick answer

US patent 7345054 (Heterocyclic inhibitors of ERK2 and uses thereof) held by Vertex Pharmaceuticals Incorporated expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Mar 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P35/00